A2 Biotherapeutics

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.

Daylight Biotherapeutics

This company develops T-cell engaging therapies for cancer patients to eliminate tumours while reducing systemic immune toxicity.

CTRL Therapeutics

This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.

Clasp Therapeutics

This company develops T cell engagers that target oncogenic driver mutations to treat patients with solid tumours.

3T Biosciences

The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.

Waypoint Bio

This company develops cell therapies for solid tumours using a spatial biology and machine learning platform to assist patients with difficult-to-treat cancers.

Tango Therapeutics

This biotechnology company develops precision oncology medicines targeting genetic vulnerabilities in cancer cells for patients with solid tumours.